FDA Approved: XOSPATA — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for XOSPATA (gilteritinib) submitted by Astellas Pharma US, Inc., resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Xospata (gilteritinib)

Snippet

SUPPL AP for XOSPATA (GILTERITINIB)